| Item Type | Name |
|
Concept
|
Abdominal Neoplasms
|
|
Concept
|
Neoplasms, Multiple Primary
|
|
Concept
|
Pelvic Neoplasms
|
|
Concept
|
Neurofibromatosis 1
|
|
Concept
|
Peripheral Nervous System Neoplasms
|
|
Concept
|
Head and Neck Neoplasms
|
|
Concept
|
Spinal Neoplasms
|
|
Concept
|
Thoracic Neoplasms
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Nervous System Neoplasms
|
|
Concept
|
Meningeal Neoplasms
|
|
Concept
|
Skin Neoplasms
|
|
Concept
|
Nerve Sheath Neoplasms
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Neurofibromatosis 2
|
|
Concept
|
Neurofibromatoses
|
|
Academic Article
|
Do NF1 gene deletions result in a characteristic phenotype?
|
|
Academic Article
|
A child with neurofibromatosis-1 and a lumbar epidural arteriovenous malformation.
|
|
Academic Article
|
Late-onset neurofibromatosis in a liver transplant recipient.
|
|
Academic Article
|
CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions.
|
|
Academic Article
|
Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1.
|
|
Academic Article
|
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
|
|
Academic Article
|
Clinical manifestations and management of neurofibromatosis type 1.
|
|
Academic Article
|
Defect in fatty acid oxidation: laboratory and pathologic findings in a patient.
|
|
Academic Article
|
Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development.
|
|
Academic Article
|
Serum dicarboxylic acids in patients with Reye syndrome.
|
|
Academic Article
|
The ophthalmologic presentation of NF-2 in childhood.
|
|
Academic Article
|
Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation.
|
|
Academic Article
|
Cognitive and psychosocial phenotype of young children with neurofibromatosis-1.
|
|
Academic Article
|
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
|
|
Academic Article
|
Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
|
|
Academic Article
|
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation.
|
|
Academic Article
|
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.
|
|
Academic Article
|
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.
|
|
Academic Article
|
Dural Ectasia in Neurofibromatosis 1: Case Series, Management, and Review.
|
|
Academic Article
|
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
|
|
Academic Article
|
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.
|
|
Academic Article
|
Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1.
|
|
Academic Article
|
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
|
|
Academic Article
|
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
|
|
Concept
|
Patient Reported Outcome Measures
|
|
Concept
|
Patient Outcome Assessment
|
|
Academic Article
|
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
|